Back to results
US 11,951,231 B2Granted
Therapeutic agent for intervertebral disc degeneration and material for culturing inter vertebral disc cells
AssigneeKinki University
InventorsTakashi Yurube, Yoshiki Takeoka, Koichi Morimoto, Saori Kunii, Kaoru Omae
Life of this patent
Estimating the term…
Abstract
A therapeutic agent for intervertebral disc degeneration that contains LASCol obtained by enzymatically cleaving a terminus of collagen.
Claims6
A therapeutic agent for intervertebral disc degeneration, comprising:
- Low Adhesive Scaffold Collagen (LASCol) at a concentration of 21 mg/ml or higher, and
- a growth factor, wherein the growth factor is a compound selected from the group consisting of Osteogenic Protein-1 (OP-1), bFGF, TGF-β1, GDF-5, BMP2, VEGF, and IGF-1;
- wherein the LASCol is in a gel state, wherein the LASCol contains a degradation product of collagen or atelocollagen in which a chemical bond between Y1 and Y2 of an al chain is cleaved in an amino-terminal amino acid sequence including a triple helical domain of the collagen or atelocollagen, the sequence being shown by the following (A), or a chemical bond between G and X3 of an α2 chain is cleaved in an amino-terminal amino acid sequence including a triple helical domain of the collagen or atelocollagen, the sequence being shown by the following (B),
- (SEQ ID NO:
- 1)
- (A)-Y1-Y2-Y3-G-Y4-Y5-G-Y6-Y7-G-Y8-Y9-G-
- (where G represents glycine, and Y1 to Y9 each represents an amino acid),
- (SEQ ID NO:
- 2)
- (B)-G-X1-X2-G-X3-X4-G-X5-X6-G-
- (where G represents glycine, and X1 to X6 each represents an amino acid).
8 more elements
A material for culturing intervertebral disc cells, comprising:
- Low Adhesive Scaffold Collagen (LASCol) at a concentration of 21 mg/ml or higher, and
- a growth factor, wherein the growth factor is a compound selected from the group consisting of Osteogenic Protein-1 (OP-1), bFGF, TGF-β1, GDF-5, BMP2, VEGF, and IGF-1;
- wherein the LASCol is in a gel state, wherein the LASCol contains a degradation product of collagen or atelocollagen in which a chemical bond between Y1 and Y2 of an α1 chain is cleaved in an amino-terminal amino acid sequence including a triple helical domain of the collagen or atelocollagen, the sequence being shown by the following (A), or a chemical bond between G and X3 of an α2 chain is cleaved in an amino-terminal amino acid sequence including a triple helical domain of the collagen or atelocollagen, the sequence being shown by the following (B),
- (SEQ ID NO:
- 1)
- (A)-Y1-Y2-Y3-G-Y4-Y5-G-Y6-Y7-G-Y8-Y9-G-
- (where G represents glycine, and Y1 to Y9 each represents an amino acid),
- (SEQ ID NO:
- 2)
- (B)-G-X1-X2-G-X3-X4-G-X5-X6-G-
- (where G represents glycine, and X1 to X6 each represents an amino acid).
8 more elements
Dependencies are inferred from the claim text.